Can gabapentin or memantine stop the shakes in MS eyes?
NCT ID NCT01744444
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested two drugs, gabapentin and memantine, in 10 people with multiple sclerosis who have a constant eye shaking called pendular nystagmus. The goal was to see if either drug could reduce the eye movement and improve vision and quality of life. Each person tried both drugs in a random order, and the researchers measured eye speed, clarity of sight, and how bothersome the shaking felt.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- gabapentin and memantine
- What this could lead to
- If it works, this could point toward a treatment to calm eye shaking and improve vision in people with multiple sclerosis.
- What could go wrong
- This is a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The drugs may cause side effects or not improve symptoms significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
10 people
The number who actually took part.
- Start date
-
Nov 2012
- Finished
-
Jul 2013
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the Mac Donald criteria. * All patients may present a chronic acquired pendular nystagmus due to MS, observed over a period of 6 months. * All patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee. * Age: above 18 * Able to understand the instructions * Having a health coverage * Able to sit down for 1 hour * Stable dosage of previous medications (beginning 3 weeks previously and terminating at the end of the trial duration), except for steroids, gabapentin or memantine. Exclusion Criteria: * Ophthalmological * Other ophthalmological disorder that could impair corrected visual acuity (Maculopathy, Retinopathy…) * Neurological * Ongoing seizure * Severe handicap that does not allow sitting down position for 1 hour * Suicidal behavior or risk * Treatment * Under memantine or gabapentin medication (these medications should have been stopped for at least 1 week for gabapentin and 3 weeks for memantine) * Under morphine, N-methyl-D-aspartate such as amantadine, ketamine or dextromethorphan * Steroid medication for a current relapse (beginning 3 weeks previously and terminating at the end of the trial duration) * Known hypersensitivity to memantine or gabapentin * General * Unstable medical state * Patient with a galactose intolerance, a lapp lactase deficiency or glucose-galactose malabsorption * Moderate renal failure (creatinine clearance \< 50 mL/min on bioassay dated from less than one month) * Recent heart infarction (\<3months) * Unstable congestive heart insufficiency * Unstable arterial hypertension * Leucopenia (\<2500/mm3) * Transaminase increase (\>5 time normal values) * Pregnancy (on questioning) * Tutelage or any legal protection measure
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Neurologique Unité de Neuro-Ophtalmologie
Bron, 69677, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise rebuild muscle and balance in MS?
- Can diet ease the crushing fatigue of multiple sclerosis?
- One-Time CAR-T infusion tested against progressive MS
- Can PET scans reveal hidden brain inflammation in MS?
- Can a pill rebuild the Brain's insulation? MS trial puts remyelination to the test
- Migraines and tension headaches may be hidden companions to multiple sclerosis